Viewing Study NCT03798535


Ignite Creation Date: 2025-12-24 @ 10:08 PM
Ignite Modification Date: 2025-12-31 @ 4:33 AM
Study NCT ID: NCT03798535
Status: COMPLETED
Last Update Posted: 2025-07-16
First Post: 2018-12-21
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: First Real-world Data on Unresectable Stage III NSCLC Patients Treated With Durvalumab After Chemoradiotherapy
Sponsor: AstraZeneca
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Description Module Conditions Module Design Module Outcomes Module Eligibility Module Contacts Locations Module References Module